scholarly journals Effects of Histamine H1-Antagonists on Sleep–Awake State in Rats Placed on a Grid Suspended over Water or on Sawdust

2009 ◽  
Vol 32 (1) ◽  
pp. 51-54 ◽  
Author(s):  
Shin Tokunaga ◽  
Ryuki Tsutsui ◽  
Yoshihito Obara ◽  
Takayuki Ishida ◽  
Chiaki Kamei
Keyword(s):  
Awake State ◽  
H1 Antagonists ◽  
Histamine H1 Antagonists

Renal vasodilation with ureteral occlusion and prostaglandins: attenuation by histamine H1 antagonists

1985 ◽  
Vol 249 (6) ◽  
pp. F851-F857
Author(s):  
R. O. Banks ◽  
E. D. Jacobson
Keyword(s):  
Renal Artery ◽  
Receptor Antagonist ◽  
Histamine Receptor ◽  
H2 Receptor Antagonist ◽  
Histamine H2 Receptor ◽  
Electromagnetic Flow Probe ◽  
H1 Receptor Antagonist ◽  
H1 Antagonists ◽  
Histamine H1 Antagonists ◽  
Ureteral Occlusion

We evaluated the effects of histamine receptor antagonists on the renal vasodilatory responses to ureteral occlusion (UO), to the intrarenal infusion of prostaglandins E2, I2, A2, D2 and E1, and to bradykinin. We also determined the effects of meclofenamic acid, a cyclooxygenase inhibitor, on histamine-induced renal vasodilation and the effects of 2-methylhistamine (2-MeH), and H1 agonist, on glomerular filtration rate (GFR) and renal blood flow (RBF). Experiments were performed on adult mongrel dogs anesthetized with pentobarbital sodium. RBF was measured with an electromagnetic flow probe. Neither UO-induced nor prostaglandin- (PG) induced renal vasodilation was affected by infusion of the histamine H2 receptor antagonist cimetidine into the renal artery at 10(-5) M/min. On the other hand, renal artery infusion of the H1 receptor antagonist chlorpheniramine (CP) at 10(-5) M/min blocked UO-induced renal vasodilation [RBF increased 34 +/- 4% (SE) prior to but only 2 +/- 2% during infusion of CP) and markedly attenuated PGI2-, PGA2-, and PGE2-induced increases in RBF (CP inhibited 64 +/- 9% of the PGE2-induced renal vasodilation). CP had less effect on the renal vasodilation associated with infusion of PGD2 or PGE1 and had no effect on the vasodilation induced by bradykinin. Infusion of exogenous histamine (1 micrograms X kg-1 X min-1) into the renal artery prior to ureteral occlusion resulted in a typical H1 + H2-mediated vasodilatory response (RBF increased 53 +/- 7%).(ABSTRACT TRUNCATED AT 250 WORDS)

Histamine H1 antagonists block M-currents in dissociated rat cortical neurons

2005 ◽  
Vol 1057 (1-2) ◽  
pp. 81-87 ◽  
Author(s):  
Ikuko Sato ◽  
Mitsutoshi Munakata ◽  
Kazuie Iinuma
Keyword(s):  
Cortical Neurons ◽  
Rat Cortical Neurons ◽  
H1 Antagonists ◽  
Histamine H1 Antagonists

Loss of skeletal integrity in rat fetuses from dams treated with histamine H1 antagonists

1993 ◽  
Vol 38 (3-4) ◽  
pp. C185-C187 ◽  
Author(s):  
G. Sturman ◽  
P. Freeman ◽  
A. R. Bailey ◽  
H. M. Meade ◽  
N. A. Seeley
Keyword(s):  
Rat Fetuses ◽  
Skeletal Integrity ◽  
H1 Antagonists ◽  
Histamine H1 Antagonists

Rat fetal and postnatal development after treatmentin utero with histamine H1 antagonists

1995 ◽  
Vol 44 (S1) ◽  
pp. S74-S75
Author(s):  
G. Sturman ◽  
P. Freeman ◽  
H. M. Meade ◽  
N. A. Seeley
Keyword(s):  
Postnatal Development ◽  
H1 Antagonists ◽  
Histamine H1 Antagonists

Proconvulsive effects of histamine H1-antagonists on electrically-induced seizure in developing mice

1993 ◽  
Vol 112 (2-3) ◽  
pp. 199-203 ◽  
Author(s):  
Hiroyuki Yokoyama ◽  
Kenji Onodera ◽  
Kazuie Iinuma ◽  
Takehiko Watanabe
Keyword(s):  
H1 Antagonists ◽  
Histamine H1 Antagonists ◽  
Developing Mice

scholarly journals An Update on Assessment, Therapeutic Management, and Patents on Insomnia

2021 ◽  
Vol 2021 ◽  
pp. 1-19
Author(s):  
Amit Porwal ◽  
Yogesh Chand Yadav ◽  
Kamla Pathak ◽  
Ramakant Yadav
Keyword(s):  
Behavioural Therapy ◽  
Pharmacological Treatments ◽  
Pharmacological Agents ◽  
Family Doctors ◽  
Cognitive Behavioural ◽  
Melatonin Receptor Agonists ◽  
H1 Antagonists ◽  
Histamine H1 Antagonists

Insomnia is an ordinary situation related to noticeable disability in function and quality of life, mental and actual sickness, and mishappenings. It represents more than 5.5 million appointments to family doctors every year. Nonetheless, the ratio of insomniacs who are treated keeps on being low, demonstrating the requirement for proceeding with advancement and dispersal of effective treatments. Accordingly, it becomes significant to provide a compelling treatment for clinical practice. It indicates a need for the determination of various critical viewpoints for the evaluation of insomnia along with various accessible alternatives for treatment. These alternatives incorporate both nonpharmacological therapy, specifically cognitive behavioural therapy for insomnia, and a number of pharmacological treatments like orexin antagonists, “z-drugs,” benzodiazepines, selective histamine H1 antagonists, nonselective antihistamines, melatonin receptor agonists, antipsychotics, antidepressants, and anticonvulsants. Besides in individuals whose insomnia is due to restless leg syndrome, depression/mood disorder, or/and circadian disturbance, there is insignificant proof favouring the effectiveness of different prescriptions for the treatment of insomnia though they are widely used. Other pharmacological agents producing sedation should be prescribed with care for insomnia therapy because of greater risk of next-day sleepiness along with known adverse effects and toxicities. This review is also aimed at providing an update on various patents on dosage forms containing drugs for insomnia therapy.

Sign in / Sign up

Export Citation Format

Share Document